-- Gerhard Fromel, DIPL. Ing, the authorized European representative for CPC with more than 25 years of experience in medical research, development and regulatory affairs in the European Union.
Further, the Web site displays an animated demonstration of the MedClose(TM) VCS in action. The animation highlights the unique design features of the MedClose(TM) VCS, which are intended to allow for significant reduction in time to hemostasis and need for manual compression. The MedClose(TM) device is intended for use with any approved natural fibrin sealant, leaving no permanent implant behind.
CPC Chairman President and CEO Rod Shipman said, "As we move closer to commercialization, we have upgraded our Web site to ensure that the medical and investment communities understand both our company and our products. We
will continue to populate the site with additional content and our latest news to keep our important constituents well informed."
CPC of America, Inc. (CPC) is focused on designing, developing and commercializing innovative medical devices that deliver improved safety and effectiveness and enhance the quality of patient care in endovascular procedures. CPC's is currently developing MedClose(TM), an investigational*- stage vascular closure system (VCS) that is intended to seal the femoral arterial puncture site following diagnostic or interventional catheterization procedures.
Forward Looking Statements
The statements contained in this press release that are not historical
are "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended (the "Securities Act"), and Section 21E
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
including statements, without l
|SOURCE CPC of America, Inc.|
Copyright©2008 PR Newswire.
All rights reserved